Cogent Biosciences, Inc. (COGT)

NASDAQ • Healthcare

$31.02

-$0.57 (-1.8%)

Market closed

Last close at October 2, 2026 at 20:00 UTC

Open$32.12

Day Range$30.86 - $32.29

Avg. Volume (3M)2.1M

Market Cap$5.3B

52 Week Range

$13.78$43.73

Next EarningsIn 33 daysNov 6, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$377.1M

EPS (TTM)

-$2.31

ROA (TTM)

-45.2%

Current Ratio

13.57

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+3.6%Q3 2025-$0.53

+7.4%Q4 2025-$0.5

-7.8%Q1 2026-$0.55

0.0%Q2 2026-$0.53

+6.3%Q3 2026-$0.52

Nov 6

in 33 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +6.3%

Cogent Biosciences’ loss per share narrowed versus expectations in the second fiscal quarter of 2026, with EPS of -$0.52 topping the -$0.55 estimate by $0.03, based on preliminary results reported August 10, 2026. The company posted net income of about -$96.4 million, down 31.1% year over year from -$73.5 million a year ago, alongside operating income of roughly -$102.6 million. Cash burn remained significant, with negative operating cash flow of about -$77.3 million for the quarter. For the next period, consensus calls for EPS of -$0.57 on revenue of $750,000.00.

View full earnings history

About Cogent Biosciences, Inc.

Cogent Biosciences, Inc. is a NASDAQ-listed Biotechnology company in the healthcare sector developing precision medicines for genetically defined diseases. Trading as COGT on the NASDAQ Global Select Market, it is an early-stage biotech founded in 2014 and based in Waltham, Massachusetts.

Name

Cogent Biosciences, Inc.

CEO

Andrew R. Robbins

Website

www.cogentbio.com

Industry

Healthcare

Year Founded

2014

Employees

258

Today's Snapshot

AI-generated

The day ended with COGT 1.8% lower at 31.02, while its sector was flat. Shares changed hands at about half of its usual level.

Trading Volume

Below 10d avg (2.2M)

vs S&P 500 Today

Underperforming Market

-2.58%

Updated: October 2, 2026 at 20:14 UTC

Technical Indicators

0 Buy3 Neutral5 Sell

COGT registers a strong sell profile as the stock trades below nearly every moving average, including the 200-day level, indicating pervasive downward pressure across timeframes. Momentum indicators are weak and MACD is negative, while ADX in the low 20s shows only moderate trend strength but no support from buying volume, as OBV is negative. Volatility is moderate and the classic pivot sits above the current price, reinforcing resistance. These factors combine to a broadly bearish technical picture. Technical takeaway: overall technicals indicate a strong sell stance.

All signals